Literature DB >> 12735139

Hepatic resection after down-staging of unresectable hepatic colorectal metastases.

René Adam1, Emmanuel Huguet, Daniel Azoulay, Denis Castaing, Francis Kunstlinger, Francis Levi, Henri Bismuth.   

Abstract

Half of the patients with colorectal cancer present with liver metastases at some point in their illness. Surgical resection, which offers the only chance of long-term survival, is an option in only 15% of patients at presentation. Novel chemotherapeutic treatments have enabled approximately 15% of those patients initially deemed inoperable to be down-staged to a point where surgery becomes an option. This aggressive approach, which requires close collaboration between surgeons and oncologists, results in a 40% 5-year survival rate, which is similar to that of patients operated without neoadjuvant chemotherapy. The hope for the future is the development of more effective chemotherapeutic regimens, which may allow more previously unresectable patients to benefit from curative surgery. This article reviews the literature and major areas of progress in treatments for unresectable colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12735139     DOI: 10.1016/s1055-3207(02)00085-6

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  8 in total

1.  Open liver resection for colorectal metastases: better short- and long-term outcomes in patients potentially suitable for laparoscopic liver resection.

Authors:  Fenella K S Welsh; Paris P Tekkis; Timothy G John; Myrddin Rees
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

Review 2.  Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: a literature review of randomized control trials.

Authors:  Peng Wang; Zhen Chen; Wen-Xia Huang; Lu-Ming Liu
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

3.  Prognostic factors and time-related changes influence results of colorectal liver metastases surgical treatment: a single-center analysis.

Authors:  Josep Martí; María Marta Modolo; Josep Fuster; Jaume Comas; Rebeca Cosa; Joana Ferrer; Victor Molina; Juan Romero; Constantino Fondevila; Ramón Charco; Juan Carlos García-Valdecasas
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

4.  Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer.

Authors:  Marcella Arru; Luca Aldrighetti; Renato Castoldi; Saverio Di Palo; Elena Orsenigo; Marco Stella; Carlo Pulitanò; Francesca Gavazzi; Gianfranco Ferla; Valerio Di Carlo; Carlo Staudacher
Journal:  World J Surg       Date:  2008-01       Impact factor: 3.352

5.  Hepatic resections using a water-cooled, high-density, monopolar device: a new technology for safer surgery.

Authors:  Isidoro Di Carlo; Francesco Barbagallo; Adriana Toro; Maria Sofia; Tommaso Guastella; Ferdinando Latteri
Journal:  J Gastrointest Surg       Date:  2004 Jul-Aug       Impact factor: 3.452

6.  A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.

Authors:  Ayhan Ulusakarya; Abdoulaye Karaboué; Oriana Ciacio; Gabriella Pittau; Mazen Haydar; Pamela Biondani; Yusuf Gumus; Amale Chebib; Wathek Almohamad; Pasquale F Innominato
Journal:  BMC Cancer       Date:  2020-06-03       Impact factor: 4.430

7.  Impact of multidisciplinary tumour boards (MTB) on the clinicopathological characteristics and outcomes of resected colorectal liver metastases across time.

Authors:  Lionel Chen; Nicholas L Syn; Brian K P Goh; Peng Chung Cheow; Prema Raj; Yexin Koh; Alexander Chung; Ser Yee Lee; London Lucien Ooi; Chung Yip Chan; Jin Yao Teo
Journal:  World J Surg Oncol       Date:  2020-09-03       Impact factor: 2.754

8.  Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.

Authors:  Oliver F Bathe; Scot Dowden; Francis Sutherland; Elijah Dixon; Charles Butts; David Bigam; Barb Walley; Dean Ruether; Scott Ernst
Journal:  BMC Cancer       Date:  2004-07-10       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.